Protected: Paige Prostate

Paige Prostate (FDA and CE-IVD) Digital Diagnostics is delivered through the FDA-cleared & CE-marked FullFocusTM viewer provides pathologists with AI-powered workflows to increase throughput and turnaround time, with greater confidence and accuracy.
| Solution Type | AI Suite/Add-on |
|---|---|
| Deployment Environment | Clinical Diagnostics |
| Regulatory Clearance | Breast Cancer – CE-IVD, Prostate Cancer – CE-IVD, Prostate Cancer – FDA Cleared |
| Target | Breast Cancer, Prostate Cancer |
| Platform Dependency | Requires Specific Platform |
| Deployment Options | Cloud-Based (SaaS) |
More Solutions from Paige
Compare Solutions
Get Pathology News Delivered to Your Inbox
Learn More
Paige News
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
Editor2026-07-21T15:31:16+00:00July 17, 2026|
Tempus AI, Inc.: A Bull Case Theory
Editor2026-02-24T12:10:21+00:00February 12, 2026|
Tempus AI, Inc. Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones
Editor2026-02-11T16:04:22+00:00February 10, 2026|
Firsthand Insights from the Paige–Tempus Acquisition & the Future of Newfound Capabilities
Editor2026-02-19T11:06:33+00:00February 9, 2026|
Tempus Announces the Acquisition of Paige
Editor2025-09-02T14:48:32+00:00August 23, 2025|
Paige and Oncoclínicas Strengthen Leadership in AI-Driven Cancer Diagnostics Across Brazil
Editor2025-08-05T22:01:12+00:00July 30, 2025|
Paige Releases PRISM2: A Whole-Slide Foundation Model for Multimodal AI in Pathology and Cancer Care
Editor2025-07-28T10:34:46+00:00July 21, 2025|












Reviews
There are no reviews yet.